{"id":2298,"date":"2009-04-16T18:55:00","date_gmt":"2009-04-16T22:55:00","guid":{"rendered":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/current-studies\/acute-hiv\/current-studies\/"},"modified":"2018-06-13T16:10:27","modified_gmt":"2018-06-13T20:10:27","slug":"current-studies","status":"publish","type":"page","link":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/faq\/current-studies\/","title":{"rendered":"Current Studies"},"content":{"rendered":"
\n

Acute HIV Studies at UNC<\/h2>\n

CID 0804:<\/span> Longitudinal (CTRC 2134) \u2013 Acute HIV Longitudinal Study<\/em><\/h2>\n\n\n\n\n
POP:<\/td>\n\n<\/td>\nIndividuals diagnosed with Acute HIV Infection<\/td>\n<\/tr>\n
CALL:<\/td>\n\n<\/td>\nFrancesca Prince, 919-966-8794 or 919-428-7612 or Caroline Baker, 919-966-2623<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

PHI 05:<\/span> QD Therapy with Dolutegravir\/Epzicom for Acute HIV Infection<\/em><\/h2>\n\n\n\n\n\n\n\n
Q:<\/td>\n\n<\/td>\nTreatment of Acute HIV Infection with one tablet once a day<\/td>\n<\/tr>\n
POP:<\/td>\n\n<\/td>\nAcute HIV infection<\/td>\n<\/tr>\n
MED:<\/td>\n\n<\/td>\nFixed-dose combination of dolutegravir and epzicom
Substudy<\/span>: Leukapheresis<\/td>\n<\/tr>\n
DUR:<\/td>\n\n<\/td>\n5 years (medication provided for 2 years)<\/td>\n<\/tr>\n
CALL:<\/td>\n\n<\/td>\nKristen Hancock, RN, 919-843-6848<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A5354: <\/span>Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses<\/em><\/h2>\n

<\/span><\/h2>\n\n\n\n\n\n\n\n
Q:<\/td>\n\n<\/td>\n\n

Timing of antiretroviral therapy (ART) during different stages of acute HIV-1 infection (AHI) will be predictive of the magnitude and characteristics of HIV-1 reservoirs, and the quantity and quality of HIV-1-specific immune responses at week 48.<\/p>\n<\/td>\n<\/tr>\n

POP:<\/td>\n\n<\/td>\n\n

Men and women 18 years and older with AHI.<\/p>\n

Group 1: Fiebig I\/II (non-reactive HIV-1 antibody)<\/p>\n

Group 2: Fiebig III\/IV (reactive HIV-1 antibody and negative or indeterminate results on the Western blot or Geenius HIV-1\/HIV-2)<\/p>\n

Group 3: Fiebig V (reactive HIV-1 antibody and positive Western blot or Geenius HIV-1\/HIV-2 without p31 band)<\/p>\n<\/td>\n<\/tr>\n

MED:<\/td>\n\n<\/td>\n\n

The antiretroviral (ARV) regimen provided through the study is the single tablet regimen elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide (EVG\/COBI\/FTC\/TAF). Other non-study-provided ARV regimens will be allowed for participants who are pregnant, breastfeeding, or unable\/unwilling to take EVG\/COBI\/FTC\/TAF, or for participants whose local health care\/primary care provider prefers starting a different initial ARV regimen.<\/p>\n<\/td>\n<\/tr>\n

DUR:<\/td>\n\n<\/td>\n\n

Up to 72 weeks.<\/p>\n<\/td>\n<\/tr>\n

CALL:<\/td>\n\n<\/td>\n\n

Kristen Hancock, RN, BSN, 919-843-6848 or Susan Pedersen, RN, 919-966-6713<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Acute HIV Studies at UNC CID 0804: Longitudinal (CTRC 2134) \u2013 Acute HIV Longitudinal Study POP: Individuals diagnosed with Acute HIV Infection CALL: Francesca Prince, 919-966-8794 or 919-428-7612 or Caroline Baker, 919-966-2623 PHI 05: QD Therapy with Dolutegravir\/Epzicom for Acute HIV Infection Q: Treatment of Acute HIV Infection with one tablet once a day POP: … Read more<\/a><\/p>\n","protected":false},"author":11751,"featured_media":0,"parent":2246,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-2298","page","type-page","status-publish","hentry","odd"],"acf":[],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/pages\/2298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/users\/11751"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/comments?post=2298"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/pages\/2298\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/pages\/2246"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/media?parent=2298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}